• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超重、肥胖与新发房颤:来自德国40万患者的真实世界证据。

Overweight, obesity and incident atrial fibrillation: Real-world evidence from 400 000 patients in Germany.

作者信息

Sedighi Jamschid, Luedde Mark, Boettger Priyanka, Bengel Philipp, Bauer Pascal, Sossalla Samuel, Rozo Sánchez Samuel Eduardo, Kostev Karel

机构信息

Medical Clinic I, Cardiology and Angiology, Justus-Liebig-University, Giessen, Germany.

Christian-Albrechts-University of Kiel, Kiel, Germany.

出版信息

Diabetes Obes Metab. 2025 Oct;27(10):5822-5830. doi: 10.1111/dom.16637. Epub 2025 Jul 22.

DOI:10.1111/dom.16637
PMID:40693361
Abstract

AIMS

Obesity is a well-established risk factor for atrial fibrillation (AF). However, the extent to which this association is driven by obesity-related comorbidities such as hypertension, diabetes and heart failure versus a potential direct effect of obesity itself remains unclear. Differentiating between these pathways is important for developing effective and targeted prevention strategies. To investigate the association between body mass index (BMI) and incident AF using both multivariable Cox regression and causal mediation analysis (CMA), quantifying the extent to which this risk is mediated by obesity-related comorbidities.

MATERIALS AND METHODS

This retrospective cohort study used the Disease Analyzer database (IQVIA) to identify patients aged ≥40 years with documented BMI in German general practices between 2005 and 2023. Patients were categorised as normal weight (18.5-24.9 kg/m), overweight (25.0-29.9 kg/m) or obese (≥30 kg/m). The primary outcome was a new diagnosis of AF within 10 years. Multivariable Cox regression models were used and adjusted for age, sex and cardiometabolic comorbidities. CMA was used to estimate the proportion of AF risk mediated through diabetes, hypertension, dyslipidaemia, coronary artery disease and heart failure.

RESULTS

Of the 392 146 patients included in the study, AF incidence was 7.2% in normal weight, 10.1% in overweight and 13.2% in obese individuals over 10 years. Obesity was associated with a significant increase in AF risk (HR 1.43; 95% CI 1.38-1.48), with a higher risk observed in men. CMA showed that 27% of the obesity-related AF risk (106% excess total risk) was mediated through comorbidities, while 79% represented a direct effect. In women, the proportion of mediated effects was higher (up to 30.1%), suggesting sex-specific differences in disease pathways.

CONCLUSIONS

Obesity significantly increases the risk of AF through both comorbidity-related and potentially independent pathways. While nearly one-third of the excess risk may be preventable through the management of cardiometabolic conditions, a notable proportion of the association remains unexplained by these mediators. These findings highlight the need for comprehensive strategies that address both obesity itself and its associated diseases to reduce the burden of AF.

摘要

目的

肥胖是心房颤动(AF)公认的危险因素。然而,这种关联在多大程度上是由肥胖相关的合并症(如高血压、糖尿病和心力衰竭)驱动的,还是肥胖本身存在潜在的直接影响,目前尚不清楚。区分这些途径对于制定有效且有针对性的预防策略很重要。本研究旨在通过多变量Cox回归和因果中介分析(CMA)来探究体重指数(BMI)与新发AF之间的关联,并量化肥胖相关合并症介导这种风险的程度。

材料与方法

这项回顾性队列研究使用疾病分析器数据库(IQVIA),以识别2005年至2023年期间在德国普通诊所中记录有BMI的≥40岁患者。患者被分为正常体重(18.5 - 24.9kg/m²)、超重(25.0 - 29.9kg/m²)或肥胖(≥30kg/m²)。主要结局是10年内新发AF诊断。使用多变量Cox回归模型,并对年龄、性别和心血管代谢合并症进行调整。CMA用于估计通过糖尿病、高血压、血脂异常、冠状动脉疾病和心力衰竭介导的AF风险比例。

结果

在纳入研究的392146例患者中,正常体重者10年内心房颤动发生率为7.2%,超重者为10.1%,肥胖者为13.2%。肥胖与AF风险显著增加相关(风险比1.43;95%置信区间1.38 - 1.48),男性的风险更高。CMA显示,27%的肥胖相关AF风险(总风险超额106%)是由合并症介导的,而79%代表直接效应。在女性中,介导效应的比例更高(高达30.1%),表明疾病途径存在性别差异。

结论

肥胖通过合并症相关途径和潜在的独立途径显著增加AF风险。虽然通过管理心血管代谢疾病可预防近三分之一的超额风险,但这些中介因素仍无法解释相当一部分关联。这些发现凸显了需要采取综合策略来应对肥胖本身及其相关疾病,以减轻心房颤动的负担。

相似文献

1
Overweight, obesity and incident atrial fibrillation: Real-world evidence from 400 000 patients in Germany.超重、肥胖与新发房颤:来自德国40万患者的真实世界证据。
Diabetes Obes Metab. 2025 Oct;27(10):5822-5830. doi: 10.1111/dom.16637. Epub 2025 Jul 22.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
4
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
5
Association between weight loss and reproductive outcomes among women with overweight or obesity: a cohort study using UK real-world data.超重或肥胖女性体重减轻与生殖结局之间的关联:一项使用英国真实世界数据的队列研究。
Hum Reprod. 2025 Jul 6. doi: 10.1093/humrep/deaf122.
6
[Association between obesity and the risk of microvascular complications in Yinzhou District, Ningbo adults with type 2 diabetes mellitus].[宁波鄞州区2型糖尿病成年患者肥胖与微血管并发症风险的相关性]
Wei Sheng Yan Jiu. 2025 Jul;54(4):608-620. doi: 10.19813/j.cnki.weishengyanjiu.2025.04.012.
7
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.孕期超重或肥胖女性使用二甲双胍以改善母婴结局。
Cochrane Database Syst Rev. 2018 Jul 24;7(7):CD010564. doi: 10.1002/14651858.CD010564.pub2.
8
Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study.脂蛋白(a)水平升高与新发心房颤动相关:一项回顾性队列研究的见解
Eur J Prev Cardiol. 2025 Jul 14;32(9):769-777. doi: 10.1093/eurjpc/zwaf063.
9
Effectiveness of systematic screening for the detection of atrial fibrillation.系统性筛查用于检测心房颤动的有效性。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD009586. doi: 10.1002/14651858.CD009586.pub2.
10
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药
Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4.